The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Sarm1-Mediated Axon Degeneration Requires Both SAM and TIR Interactions
Open accessAbstract
Axon degeneration is an evolutionarily conserved pathway that eliminates damaged or unneeded axons. Manipulation of this poorly understood pathway may allow treatment of a wide range of neurological disorders. In an RNAi-based screen performed in cultured mouse DRG neurons, we observed strong suppression of injury-induced axon degeneration upon knockdown of Sarm1 [SARM (sterile α-motif-containing and armadillo-motif containing protein)]. We find that a SARM-dependent degeneration program is engaged by disparate neuronal insults: SARM ablation blocks axon degeneration induced by axotomy or vincristine treatment, while SARM acts in parallel with a soma-derived caspase-dependent pathway following trophic withdrawal. SARM is a multidomain protein that associates with neuronal mitochondria. Deletion of the N-terminal mitochondrial localization sequence disrupts SARM mitochondrial localization in neurons but does not alter its ability to promote axon degeneration. In contrast, mutation of either the SAM (sterile α motif) or TIR (Toll-interleukin-1 receptor) domains abolishes the ability of SARM to promote axonal degeneration, while a SARM mutant containing only these domains elicits axon degeneration and nonapoptotic neuronal death even in the absence of injury. Protein–protein interaction studies demonstrate that the SAM domains are necessary and sufficient to mediate SARM–SARM binding. SARM mutants lacking a TIR domain bind full-length SARM and exhibit strong dominant-negative activity. These results indicate that SARM plays an integral role in the dismantling of injured axons and support a model in which SAM-mediated multimerization is necessary for TIR-dependent engagement of a downstream destruction pathway. These findings suggest that inhibitors of SAM and TIR interactions represent therapeutic candidates for blocking pathological axon loss and neuronal cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992
RetractedThe Pfam protein families database
Finn, R. D., Mistry, J., Tate, J., Coggill, P., Heger, A., Pollington, J. E., Gavin, O. L., Gunasekaran, P., Ceric, G., Forslund, K., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp985 · Cited by 2,694
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667
Parvalbumin neurons and gamma rhythms enhance cortical circuit performance
Sohal, V. S., Zhang, F., Yizhar, O., & Deisseroth, K. (2009) · Nature · doi:10.1038/nature07991 · Cited by 2,606
Programmed Cell Death in Animal Development and Disease
Fuchs, Y., & Steller, H. (2011) · Cell · doi:10.1016/j.cell.2011.10.033 · Cited by 1,915
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
Araki, T., Sasaki, Y., & Milbrandt, J. (2004) · Science · doi:10.1126/science.1098014 · Cited by 1,060
Self-citationResveratrol stimulates AMP kinase activity in neurons
Dasgupta, B., & Milbrandt, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610068104 · Cited by 723
Self-citation
Cited by
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865
Essuman, K., Summers, D. W., Sasaki, Y., Mao, X., DiAntonio, A., & Milbrandt, J. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.022 · Cited by 619
Self-citationSARM1 activation triggers axon degeneration locally via NAD + destruction
Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A., & Milbrandt, J. (2015) · Science · doi:10.1126/science.1258366 · Cited by 593
Self-citationSARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration
Figley, M. D., Gu, W., Nanson, J. D., Shi, Y., Sasaki, Y., Cunnea, K., Malde, A. K., Jia, X., Luo, Z., Saikot, F. K., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.02.009 · Cited by 324
Self-citationRetrograde Axonal Degeneration in Parkinson Disease
Tagliaferro, P., & Burke, R. E. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150769 · Cited by 272
NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD+ depletion
Sasaki, Y., Nakagawa, T., Mao, X., DiAntonio, A., & Milbrandt, J. (2016) · eLife · doi:10.7554/elife.19749 · Cited by 192
Self-citationMetabolic stress drives sympathetic neuropathy within the liver
Liu, K., Yang, L., Wang, G., Liu, J., Zhao, X., Wang, Y., Li, J., & Yang, J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.012 · Cited by 146
Goyal, M. S., Venkatesh, S., Milbrandt, J., Gordon, J. I., & Raichle, M. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511465112 · Cited by 141
Self-citationGene therapy targeting SARM1 blocks pathological axon degeneration in mice
Geisler, S., Huang, S. X., Strickland, A., Doan, R. A., Summers, D. W., Mao, X., Park, J., DiAntonio, A., & Milbrandt, J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181040 · Cited by 145
Self-citationLiu, H.-W., Smith, C. B., Schmidt, M. S., Cambronne, X. A., Cohen, M. S., Migaud, M. E., Brenner, C., & Goodman, R. H. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809392115 · Cited by 105
Metabolic Vulnerability in the Neurodegenerative Disease Glaucoma
Inman, D. M., & Harun-Or-Rashid, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00146 · Cited by 88
Murata, H., Khine, C. C., Nishikawa, A., Yamamoto, K.-I., Kinoshita, R., & Sakaguchi, M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004578 · Cited by 80
Low levels of NMNAT2 compromise axon development and survival
Gilley, J., Mayer, P. R., Yu, G., & Coleman, M. P. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy356 · Cited by 62
Non-apoptotic cell death in animal development
Kutscher, L. M., & Shaham, S. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.20 · Cited by 67
SARM1, Not MyD88, Mediates TLR7/TLR9-Induced Apoptosis in Neurons
Mukherjee, P., Winkler, C. W., Taylor, K. G., Woods, T. A., Nair, V., Khan, B. A., & Peterson, K. E. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500953 · Cited by 64
Implications of NAD metabolism in pathophysiology and therapeutics for neurodegenerative diseases
Hikosaka, K., Yaku, K., Okabe, K., & Nakagawa, T. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1637504 · Cited by 62
SARM1 signaling mechanisms in the injured nervous system
Sambashivan, S., & Freeman, M. R. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.05.004 · Cited by 46
Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy
Coleman, M. P. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01297-6 · Cited by 33
“SARM1 is particularly well known for its profound effects in killing axons [3, 4].”
BackgroundProgressive axonopathy when oligodendrocytes lack the myelin protein CMTM5
Buscham, T. J., Eichel-Vogel, M. A., Steyer, A. M., Jahn, O., Strenzke, N., Dardawal, R., Memhave, T. R., Siems, S. B., Müller, C., Meschkat, M., et al. (2022) · eLife · doi:10.7554/elife.75523 · Cited by 18
Miller, S. J., Darji, R. Y., Walaieh, S., Lewis, J. A., & Logan, R. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1271941 · Cited by 16
SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy
Ding, C., Ndiaye, P. S., Campbell, S. R., Fry, M. Y., Gong, J., Wienbar, S. R., Gibbs, W., Morquette, P., Chao, L. H., Do, M. T. H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191315 · Cited by 8
Metadata
- Authors
- Gerdts, J., Summers, D. W., Sasaki, Y., DiAntonio, A., & Milbrandt, J.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2013-08-14
- Volume
- 33
- Issue
- 33
- Pages
- 13569-13580
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1997393571
- Cited by
- 375
- References
- 7
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
